Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
RFK Jr.'s handpicked vaccine panel just voted to stop recommending hepatitis B shots for all newborns. Why experts object. - 2Step by step instructions to Pick the Right Web-based Degree Program
- 3Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
- 4What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
- 5Fundamental Home Items Each Animal person Needs
- EU chief urges Iran to free imprisoned protesters, lift internet ban
- Which Store is Your Decision ?
- Turkey key underlying issue as Israel, Greece, Cyprus hold summit
- A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
- Finding Your Motivation: Moves toward a Satisfying Life
- Venezuelans in Madrid celebrate Maduro's capture
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Investigating the Financial History of the World: A Succinct Outline
- What to know about the hepatitis B shot — and why Trump officials are targeting it
